OUR VISION
Our vision is to harness insights from the global Zoroastrian-Parsi community and other relevant populations to accelerate identification of validated predictive biomarkers and accelerate delivery of drugs and companion diagnostic tests for patient-centric treatments at an acceptable cost proposition to developing healthcare countries. AGENOME investigates the molecular basis of longevity and age-related disorders, prioritizing cancers, cardiovascular disease, diabetes, neurological disorders.
The 10,000 Avestagenome Project® is a large vision one of a kind initiative to harness the genomic potential of the endogamous communities of India for understanding human disease and development of the next generation of omics-led precision medicine and diagnostics.
Harnessing Genomic Potential
The Avestagenome Project®
AGENOME combines state-of-the-art systems biology “omics” with advanced sequencing, data analytics, machine learning and longitudinal datasets from the Zoroastrian-Parsi community which serves as a control to other global population datasets. Comparing and contrasting disease states and lifelong patient healthcare datasets with deep data-mining, in-vivo data from medical imaging and monitoring equipment will provide better qualified biomarkers leading to faster and more accurate identification of druggable targets, reducing the risk of costly and time-consuming drug development failures and accelerating the delivery of associated predictive diagnostic tests and drugs.
Rare Comprehensive Biobank
Unique Endogamous Population
The Avestagenome Project® was created to identify within the Zoroastrian-Parsi population, genetic risk factors that predispose individuals to cancers, elucidate gene function and improve public health through early intervention, improving disease prevention strategies and delivering improved population and patient health outcomes.
It is the largest epidemiological study ever conducted on a consanguineous population and the first detailed system biology study worldwide on an endogamous population. The project has collected a biobank of blood samples with extensive patient data from its first cohort of 4,700 Zoroastrian-Parsis and is dedicated to the identification and delivery of predictive biomarkers and druggable targets.
Global Health Paradigm Shift
Synergizing Population Genomic Consortiums Worldwide
The Avestagenome Project® has been identified to be of significant interest for the study of ageing, lifestyle and inherited disorders, as well as enhancing the genomic diversity of global genomic repositories and large population genomic consortiums. The outcomes from the 10,000 Zoroastrian Parsi genome study will be of significant relevance for global communities, Asian and other ethnicities besides the target community. This population genomics study will contribute to reducing healthcare costs through individual patient-based pharmacogenomics driven treatments provided by in depth genomic insights.
Global Partner Network
Population Genomics Driven Biomarker Discovery
AGENOME is powered by a network of global partners. We encourage and look for collaborations with innovative thinkers, academia, medical professionals, hospitals, R&D institutions, communities and social service platforms.
